Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 6.3% – Time to Sell?

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) fell 6.3% during mid-day trading on Wednesday . The company traded as low as $6.28 and last traded at $6.30. 734,305 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 2,545,762 shares. The stock had previously closed at $6.72.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Down 0.5 %

The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock’s fifty day simple moving average is $8.78 and its two-hundred day simple moving average is $9.68. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -36.00, a P/E/G ratio of 1.51 and a beta of 0.79.

Institutional Trading of Amicus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Virtus Fund Advisers LLC bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at $29,000. Covestor Ltd grew its holdings in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amicus Therapeutics during the fourth quarter worth $59,000. GAMMA Investing LLC lifted its holdings in shares of Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 7,007 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $79,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.